FDA Matters Blog


HPS Group, LLC is a solution-oriented health policy and public affairs company. Its specialty is strategic counsel that integrates the perspectives of Congress, the Executive Branch, third parties, and the media. The company philosophy is “Think. Plan. Act.”

Because of Mr. Grossman’s expertise and experience, HPS Group (www.HPSGroup.com) is often asked to partner with larger firms in assisting clients with complex, multi-faceted projects. Whether solo or in partnership, the company’s business has five segments:

  • Health policy development and analysis
  • Regulatory counsel/scientific communications
  • Coalition development
  • Washington representation and lobbying
  • FDA advisory committee preparation

In addition to being an analyst, counselor and communicator, Mr. Grossman is often a facilitator for strategic planning and program development meetings. He speaks and writes on a wide range of policy topics, including communicating with FDA, incentives for drug development, understanding health care financing programs, and the impact of information technology on health care.

Background: From 1989 to 2000, Mr. Grossman was senior managing director and director of health policy in Hill and Knowlton’s Washington office. He developed and implemented public affairs, communications and crisis management programs for health care, pharmaceutical and food clients. He also counseled clients on policy, strategy, corporate communications, regulation, and legislation.

In 1985, Mr. Grossman was appointed by President Ronald Reagan to serve as a Deputy Assistant Secretary for Health in the U.S. Department of Health and Human Services. During his four-year tenure, he was responsible for the development of health policy, planning, and evaluation for the U.S. Public Health Service. Among his accomplishments, he chaired the “long-term care” component of the Secretary’s initiative on catastrophic health care costs, coordinated the President’s response to his Commission on HIV Infection and AIDS, and served as Acting Chair of the Orphan Product Board.

Previously, Mr. Grossman was Health Staff Director and Majority Counsel to the Senate Committee on Labor and Human Resources, under its Chairman, Senator Orrin Hatch. He was one of the chief Senate negotiators on the Orphan Drug Act of 1983 and on the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman). These laws have had significant and lasting impact on the development of new pharmaceutical products. Earlier in his career, while at the Association of American Medical Colleges, he was an analyst and advocate for the nation’s medical schools.

Additional Information: Mr. Grossman received a J.D. from Georgetown University Law Center in 1976 and a BA from Oberlin College in 1973. In 2006, he founded and became the executive director of the FDA Alliance, a multi-stakeholder coalition advocating for increased appropriated resources for FDA. In January 2008, the Alliance merged with another advocacy group and became the Alliance for a Stronger FDA (www.StrengthenFDA.org). He serves as the organization’s Deputy Executive Director.

Click FDA Matters logo at top of this page to return to the home page.

© 2009-2012 by HPS Group. All rights reserved. Permission is hereby granted to those wishing to quote or reprint from this site, providing it is properly attributed to FDA Matters: The Grossman FDA Report™.